Background: Dabigatran is an oral direct thrombin inhibitor recently approved for stroke
prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

The use of novel anticoagulants such as dabigatran are increasing. Despite increased risks
of intracerebral haemorrhage with warfarin among Asians, there is little published data on …

Background—Recent studies have investigated alternatives to warfarin for stroke
prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost …

Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Background: The Asian population with atrial fibrillation (AF) have a higher risk of stroke
than the caucasian population and a higher risk of intracranial bleeding when …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of
safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 …

BACKGROUND: Dabigatran is a recently introduced direct thrombin inhibitor licensed for
use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our …